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Abstract
Background: Amifostine is an efficient cytoprotector against toxicity caused by some chemotherapeutic drugs.
Doxorubicin, a potent anticancer anthracycline, is known to produce spermatogenic damage even in low doses.
Although some studies have suggested that amifostine does not confer protection to doxorubicin-induced
testicular damage, schedules and age of treatment have different approach depending on the protocol. Thus, we
proposed to investigate the potential cytoprotective action of amifostine against the damage provoked by
doxorubicin to prepubertal rat testes (30-day-old) by assessing some macro and microscopic morphometric
parameters 15, 30 and 60 days after the treatment; for fertility evaluation, quantitative analyses of sperm
parameters and reproductive competence in the adult phase were also carried out.
Methods: Thirty-day-old male rats were distributed into four groups: Doxorubicin (5 mg/kg), Amifostine (400 mg/
kg), Amifostine/Doxorubicin (amifostine 15 minutes before doxorubicin) and Sham Control (0.9% saline solution).
“Standard One Way Anova” parametric and “Anova on Ranks” non-parametric tests were applied according to the
behavior of the obtained data; significant differences were considered when p < 0.05.
Results: The rats killed 30 and 60 days after doxorubicin treatment showed diminution of seminiferous epithelium
height and reduction on the frequency of tubular sections containing at least one type of differentiated
spermatogonia; reduction of sperm concentration and motility and an increase of sperm anomalous forms where
observed in doxorubicin-treated animals. All these parameters were improved in the Amifostine/Doxorubicin group
only when compared to Doxorubicin group. Such reduction, however, still remained below the values obtained
from the Sham Control group. Nevertheless, the reproductive competence of doxorubicin-treated rats was not
improved by amifostine pre-administration.
Conclusions: These results suggest that amifostine promotes a significant reduction of the doxorubicin long-term
side effects on the seminiferous epithelium of prepubertal rats, which is reflected in the epidydimal fluid
parameters in the adult phase. However, fertility status results suggest that such protection may not be effective
against sperm DNA content damage. Further investigation of sperm DNA integrity must be carried out using
amifostine and doxorubicin-treated experimental models.
Background
A perfect chemotherapeutic treatment would selectively
attack tumor cells without causing toxicity on normal
tissues. Unfortunately, this ideal selectivity has not yet
been reached by traditional chemotherapy, which is
known to affect both neoplastic and proliferating normal
cells [1]. Modern therapies using multiple combinations
of chemotherapeutic drugs reduce the cytotoxicity of
these drugs to normal tissues, increasing the survival
rates [2]. However, even after increasing the effective-
ness of these treatments, many patients present post-
chemotherapy sterility for about 5 years [3-5]. Besides,
children and young patients exposed to chemotherapy
in prepubertal phase can yet show irreversible impair-
ment or loss of fertility status [6].* Correspondence: vane.vanila@gmail.com1Developmental Biology Laboratory, Department of Morphology and
Genetics, Federal University of São Paulo (UNIFESP), São Paulo-SP, Brazil
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Among various antineoplastic agents, doxorubicin, an
anthracycline compound, is one of the most used antic-
ancer drugs. Doxorubicin has recognized effectiveness
against solid and non-solid malignant tumors and is
used in oncology protocols against malignancies such as
Hodgkin disease, childhood leukemia and testicular can-
cer, which commonly affect young patients and children
[3,6]. Nonetheless, it is responsible for long and short-
term male infertility [7,8]. The preferential target of
doxorubicin is the DNA of dividing cells; the drug inter-
calates within DNA strands causing cell cycle blockage
in the G2 phase, single-strand breaks [9] and inhibition
of the activity of some nuclear proteins, such as DNA
and RNA-polimerase and DNA-topoisomerase II [10]. It
has been recently found that doxorubicin also interferes
with an important molecule involved in chromosome
stability and transcription, the DNA methyl-transferase
1 - DNMT1 [11], inducing apoptosis.
Clinical and experimental studies have widely demon-
strated the testicular toxicity caused by doxorubicin
[12,13]. Lu and Meistrich [14] showed that even a low
dose of doxorubicin (1 mg/kgb.w.) given to adult mice
is able to target germ cells, mainly A1-A4 spermatogo-
nia, leading to seminiferous epithelium depletion. More-
over, doxorubicin can also harm type B spermatogonia
[15] and primary spermatocytes depending on the treat-
ment schedule [14].
The fertility preservation of young patients submitted
to anticancer treatments is an important aspect that
must be considered, since the prognosis of 10-year sur-
vival after childhood leukemia has the projection to
reach 90% until the end of 2010 [3,4]. Thus, the che-
motherapy schedules also need to be improved; on this
scope, other supporting therapies must be investigated
focusing on reducing undesirable effects and providing a
better life quality to survivor patients. Amifostine, a cel-
lular protector, has been additionally used in che-
motherapy and radiotherapy with this purpose [5].
Amifostine (WR-2721) is an organic phosphorylated
thyol, which was isolated by the US Army in the 1950’s,
aiming to protect soldiers against a possible nuclear war.
Initial clinical trials were focused on the prevention of
hematotoxicities produced by radiation, cyclophospha-
mide, carboplatin and cisplatin therapies [16-18].
Besides the remarkable cytoprotection of amifostine
against toxicities and side effects provoked by che-
motherapeutic drugs, performed by its dephosphorylated
metabolite, the WR-1065 free thyol, it also exhibits
selective protection to normal cells without reducing the
antitumor drug effectiveness. This selectivity is a conse-
quence of some mechanisms that ease the capture of
WR-1065 in normal tissues, which are much more vas-
cularized than tumoral tissues [19,20]. Moreover, in
non-tumoral tissues the alkaline phosphatase has the
favorable neutral pH for its adequate activity, required
to dephosphorilate the WR2721 (amifostine) to the
active metabolite, WR-1065 [19-21]. This metabolite
acts as ROS scavenger and stabilizes intact DNA inside
normal cell nucleus, inhibiting DNA intercalation and
breakage caused by antineoplastic drug [22]; such stabi-
lity also improves the DNA ability to self-repair after
any DNA damage that might have occurred after antitu-
moral treatments [21].
Although WR-2721 is being included in anticancer
treatment schedules for both radiotherapy [5] and che-
motherapy [23], there is scarce information about its
chemical interactions and its systemic effects, especially
in young patients and children. Although some works
have been published presenting in vitro and in vivo
results after exposure of young rats to both drugs
[24-28], there are no detailed morphological studies
concerning the potential protection conferred by amifos-
tine to the seminiferous epithelium integrity and its
recovery capacity. Moreover, since many children and
adolescents have already been submitted to amifostine
treatment prior to chemotherapy protocols including
doxorubicin [5], the extension of the effects on male
reproduction still need to be answered.
Until the present moment, there is no often informa-
tion related to the fertility of patients who were simulta-
neously exposed to doxorubicin and amifostine during
childhood and adolescence. Besides, previous findings by
our group indicated that amifostine partially protects
germ cells of prepubertal rats against apoptosis caused
by cisplatin, another chemotherapeutic drug [24]. Thus,
considering the wide use of doxorubicin against malig-
nant neoplasm and the fact that infertility has become a
common consequence of these treatments, we decided
to investigate whether acute and previous administration
of amifostine to prepubertal rats can protect their semi-
niferous epithelium against the doxorubicin acute treat-
ment. For that reason, during the sexual maturation of
the rats (prepubertal, pubertal and young adult phases),
the impact of these treatments on the frequency of
germ cell types and on testicular stereological and mor-




Sixty 30-day-old male Wistar rats were distributed into
four groups: Doxorubicin (D), Amifostine (A), Amifos-
tine/Doxorubicin (AD) and Sham Control (SC). The ani-
mals were killed at 3 different times after treatment (15,
30 and 60 days after it), subdividing all the groups into
3 subgroups according to the killing ages (45-, 60- and
90-day-old rats). Thus, 12 subgroups of 5 animals each
were established. The number indicated in each
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subgroup acronym corresponds to the sacrifice age.
Additional males were included in each ninety-day-old
group (totaling 10 males per group) to evaluate their
reproductive competence. Rats were maintained under
12/12 hr light/dark cycles, at 21-23°C room temperature;
standardized lab chow (Nuvilab CR1, Nuvital®, Curitiba,
PR, Brazil) and water were provided ad libitum. This
study was approved by the Ethical Committee for Ani-
mal Research of the Federal University of São Paulo,
Brazil.
Protocols of treatment
The experimental and control groups were the following:
Sham Control group (SC), treated with 0.5 ml of 0.9% sal-
ine solution; Amifostine group (A) that received 400 mg/
kg of amifostine ("Ethyol” or WR-2721; Schering-Plough
S/A, São Paulo, Brazil); Doxorubicin group (D), treated
with 5 mg/kg of doxorubicin (Eurofarma, São Paulo, Bra-
zil); Amifostine/Doxorubicin group (AD), treated with
amifostine (400 mg/kg) 15 min prior to the doxorubicin
injection (5 mg/kg). All the treatments were given by
intraperitoneal route. Both amifostine and doxorubicin
were diluted in 0.9% of physiological saline solution imme-
diately before application, according to the manufacturer’s
instructions and were administered in single doses.
Histological procedures and histopathological analysis
Before the euthanasia, the rats were anaesthetized with
thiopental (Tiopentax; Crisália Produtos Químicos e
Farmacêuticos, São Paulo, Brazil); their testes were
removed and immersed in Bouin’s fixative for 48 hrs.
Testicular fragments were processed and Paraplast-Plus®
(Sigma-Aldrich Co., St. Louis, MO, USA) embedded.
Three μm-thick cross sections (two non-consecutive
cross sections from each testis) were stained with
Hematoxylin and Eosin or submitted to the Periodic
Acid-Schiff (PAS) method and counterstained with
Hematoxylin (PAS+H). The PAS+H method was used
since it is a histochemical method that assures an effi-
cient identification of spermatid steps [29]. Two hun-
dred tubular sections per animal (one hundred per
testis) were randomly analyzed using the Leica QWin
V3 (Cambridge, UK) image analysis system and ×20
objective lens. Tubular sections presenting histopatholo-
gical alterations were scrutinized and recorded using a
digital camera connected to a light microscope.
Tubular frequency according to the different germ cell
types
The frequencies of tubular sections containing each germ
cell type (spermatogonia, primary spermatocytes, round
spermatids and elongated spermatids) were obtained
[30-33]. For this aim, fifty PAS-treated seminiferous
tubule sections per testis (left and right testes) were
randomly examined at ×1000 magnification, totaling 100
tubular sections per animal. The results are expressed in
percentage. The identification of germ cell types was per-
formed according to Leblond & Clermont [29].
Stereological and morphometric analyses
Immediately after testis removal from the scrota, they
were weighted and their volumes were obtained by
Scherle’s method [34]. The volume densities (Vv) of
Tubular Lumen (VvTL), Seminiferous Epithelium
(VvEp), Lymphatic Space (VvLS) and Interstitial Tissue
(VvIT) were obtained. For this purpose, a 25-point inte-
grating eyepiece [35] was coupled to a light microscope.
Thirty random fields of right and left cross sections of
each testis were analyzed at 125× magnification, totaling
750 points per testis (1500 points per animal).
Tubular diameter and seminiferous epithelium height
of 50 random tubular cross-sections per testis were ana-
lyzed, using a micrometer eyepiece attached to a light
binocular microscope, at 80× magnification. When a
section was oblique, only the minor axis of the tubular
section was measured [25,26].
Sperm concentration, motility and morphology
Samples of epididymal cauda fluid were obtained for the
analysis of sperm concentration, motility and morphol-
ogy. All these procedures followed the consensus report
published by Seed and colleagues [36].
After properly cleaned, the left epididymis was placed
on a Petri dish containing 5 ml of 0.9% saline solution;
then, the distal part of epididymis cauda was minced
with a razor blade to allow sperm diffusion in the phy-
siological solution for 5 min, under 26-30°C. An aliquot
(50 μl) of the sperm homogenate was placed on a slide
for motility assessment. Motile (showing any kind of
movement) and non-motile (steady) sperm cells were
counted within 5 different fields. An hour after the
sperm diffusion in saline solution, sperm counts were
performed in a hematocytometer chamber (Neubauer
Bright Line Improved, 0.100 mm). Morphological ana-
lyses of spermatozoa smears of control and experimental
rats were also performed. The smears were stained using
Shorr/Hematoxylin method and the percentages of nor-
mal and abnormal spermatozoa were counted (200 sper-
matozoa/rat). The determinant abnormal characteristics
considered were: a) the shape and size of spermatozoa
head, including big or small heads, with lighter or
accentuated curvature; b) intermediary pieces defects
resulting untied heads; c) defects of tails including short,
multiple, folded or broken tails.
Reproductive competence
Each fifteen 90-day-old males from SC, A, D and AD
groups were mated with two normal primiparous
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females in proestrous. Sperm positive females were
killed at the 21st day of pregnancy to access male ferti-
lity index (the ratio between the number of live fetuses
and the number of mated females) [32].
Statistical analysis
The morphometric and stereological data were sub-
mitted to parametric and non-parametric tests using
Jandel Statistical SigmaStat software 2.0. “Standard One
Way Anova” parametric and “Anova on Ranks” non-
parametric tests were used to respectively evaluate the
statistical significance among means or medians from
the obtained data. When results showed statistical sig-
nificance, data were submitted to Student-Newman-
Keuls multiple-comparison test. Differences among the
groups were considered significant when p < 0.05.
Results
All rats treated with 400 mg/kg of amifostine (A and
AD groups) showed lethargy, shivers and piloerection
soon after the treatment. The rats only treated with
doxorubicin showed alopecia around ten days after the
treatment.
No significant differences were observed regarding the
body weight (data not shown) among the different
groups (SC, A, D, AD).
Histopathology of the seminiferous epithelium
Amifostine-treated rats of the A and AD groups showed
preserved seminiferous epithelium, with normal mor-
phology, similar to those observed in rats of the Sham
control group, at the corresponding ages (Figs. 1A, B, E,
2A, B, E, F, 3A, B, E and 3F).
Different degrees of seminiferous tubule damage were
noted in the solely doxorubicin-treated rats according to
the age they were killed. Some tubular sections of 45-
day-old doxorubicin-treated rats showed disorganized
seminiferous epithelium, with discontinuous germ cell
layers, as well as sloughed germ cells detached into the
tubular lumen (Figs. 1C and 1D). In 60-day-old doxoru-
bicin-treated rats, depletion of seminiferous epithelium,
intraepithelial vacuolization and multinucleated forma-
tions of round spermatids (Fig. 2C) were the most com-
mon alterations noted. Round spermatid nuclei with
condensed peripheral chromatin suggesting apoptosis
were also observed in tubular sections where the semini-
ferous epithelium was apparently more preserved (Fig.
2D). On the other hand, rats of 90D subgroup displayed
a more preserved seminiferous epithelium than those of
the 60D subgroup, although they still presented some
morphological damage. Germ cell loss was occasionally
observed in this subgroup (Figs. 3C and 3D). Conversely,
rat testes submitted to doxorubicin treatment, which
were previously-treated with amifostine (AD group),
showed normal concentric distribution of germ cells,
with organized layers arranged according to the cytolo-
gical differentiation degree, likewise noted in SC and A
rats (Figs. 1E, 2E, F, 3E and 3F). Occasional intraepithe-
lial vacuoles were also found in the seminiferous tubule
sections of 60AD rats (Figs. 2E and 2F). Some Sertoli
cell nuclei were displaced and showed abnormal con-
densed chromatin (Fig. 2F) in these rats.
Stereological analysis: volume densities (Vv)
The volume densities of the seminiferous epithelium,
tubular lumen, interstitial tissue and lymphatic space are
shown in Table 1.
The values of seminiferous epithelium volume density
(VvEp) were lower in the 60- and 90-day-old solely dox-
orubicin treated rats (60D and 90D subgroups) than in
rats of the other corresponding subgroups), including
those amifostine/doxorubicin treated (AD group). Con-
versely, there was a reduction of VvEp in 90-day-old
amifostine/doxorubicin treated rats (90AD subgroup) in
comparison with those of the 90A subgroup; however,
no significant differences were observed regarding this
parameter when 90AD and 90SC subgroups were
compared.
The lymphatic space volume density (VvLS) was signifi-
cantly reduced in 60-day-old amifostine-treated subgroups
in comparison to the corresponding SC and D subgroups;
however, the rats of the 90AD subgroup showed an
increase of this parameter in comparison to all other sub-
groups of the same age (90SC, 90A and 90D).
Morphometric testicular analysis
No significant differences were observed regarding the
testis weight and total testicular volume (data not
shown) among the different groups (SC, A, D, and AD).
A gradual increase of seminiferous tubule diameter
occurred from 45 to 90 days of age in all groups (Fig.
4A); however, this growth rate was significantly reduced
in amifostine-treated rats (A and AD groups) from 60 to
90 days of age, when they were compared to the SC and
D groups, as shown in the Fig. 4B. Nevertheless, from
45 to 60 days of age, rats of the D group presented a
reduced growth rate of the tubular diameter in compari-
son to all the other groups.
A considerable reduction of the seminiferous epithe-
lium height (Fig. 4C) was observed in the 60D and 90D
subgroups when they were compared to the other corre-
sponding subgroups (60SC, 90SC; 60A, 90A; 60AD and
90AD); a reduction of this parameter was also observed
in the rats of the 60AD and 90AD subgroups in com-
parison to those from the Sham Control and Amifostine
subgroups at same ages.
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Tubular frequency according to the different germ cell
types (Table 2)
In the 45D subgroup, the frequency of seminiferous
tubule sections containing intermediate spermatogonia
(GIn) was lower in comparison to those from other sub-
groups at same age (45SC, 45A and 45AD). On the con-
trary, no significant differences were observed between
45D and 45AD subgroups regarding the frequencies of
tubular sections containing types A and B spermatogo-
nia (GA and GB). Besides, this parameter was reduced
in the 45D and 45AD subgroups in comparison with
those observed in the 45SC and/or 45A subgroups.
Conversely, sixty-day old rats of D group showed a
significant reduction of the frequencies of seminiferous
tubule sections containing the three types of spermato-
gonia (GA, GIn and GB) when compared to all other
subgroups at the same age. In addition, no significant
reductions of the number of tubular sections containing
GA and GIn were observed in testes of 60AD rats in
comparison to 60SC rats.
Figure 1 Photomicrographs of testicular sections of Sham Control, Amifostine, Doxorubicin and Amifostine/Doxorubicin treated rats
at different ages. PAS+H method. Portions of tubular sections of 45-day-old rats. A and B: Sham Control (A) and Amifostine-treated (B) groups
showing organized seminiferous epithelium containing various cell types until round spermatids. Lymphatic space (LS); primary spermatocytes
(arrowheads); round spermatids (long arrows). C and D: Doxorubicin-treated group. Note in C the cellular debris and the germinal lineage cells
detached from the epithelium into the tubular lumen (short arrow); see also the discontinuous seminiferous epithelium (asterisks). In D, observe
the vacuole formation (v), the primary spermatocytes (arrowheads) and the round spermatids (long arrows). E: Amifostine/Doxorubicin-treated
group showing the organized seminiferous epithelium with normal morphology. Spermatogonia (arrows); primary spermatocytes (PS); round
spermatids (arrowheads).
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On the other hand, rats of the 90D subgroup showed
significantly reduced frequencies of tubular sections
containing GA and GB, in comparison to the other sub-
groups (including the 90AD group), except for GIn
spermatogonia type. In addition, rats of 90AD subgroup
showed a lower frequency of tubular sections containing
GA, GIn and GB than those of the 90SC and 90A
subgroups.
The frequency of tubular sections containing round
spermatids (RS) decreased in rats of the 90D subgroup
in comparison to all other subgroups at the correspond-
ing ages, including the AD group. In spite of the same
reduction was observed in the 60D subgroup, it was not
significantly lower when compared to the 60AD sub-
group. Nevertheless, 45-day-old amifostine-treated rats
(45A and 45AD subgroups) showed a reduction of
Figure 2 Photomicrographs of testicular sections of Sham Control, Amifostine, Doxorubicin and Amifostine/Doxorubicin treated rats
at different ages. PAS+H method. Portions of sections of seminiferous tubules of 60-day-old rats. A and B: Sham Control (A) and Amifostine
(B) groups. Elongated spermatids (arrows); interstitial tissue (IT); primary spermatocytes (arrowheads). C and D: Doxorubicin-treated group
displaying damaged seminiferous epithelium. In C, an accentuated epithelial depletion and various elongated spermatids, sometimes abnormally
located (arrowheads) can be observed; vacuole (asterisk); multinucleated formation in degeneration (thick arrow). In D, some spermatids showing
outlined condensed and ring-shaped marginal chromatin are observed; this event suggests apoptosis occurrence (thin arrows). Inset: detail of
round spermatids with ring-shaped marginal chromatin. E and F: Amifostine/Doxorubicin-treated group. Note the presence of morphologically
normal round (thick arrows) and elongated (long arrows) spermatids, vacuole (asterisk) and Sertoli cell nucleus dislocated from the tubular
periphery and with abnormal chromatin condensation (circle); primary spermatocytes (arrowheads); tubular lumen (TL).
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frequency of tubular sections with elongated spermatids
(ES) in comparison to the rats of 45SC and 45D
subgroups.
Concentration, motility and morphology of spermatozoa
in the epididymal fluid
In the 90AD subgroup, all sperm parameters analyzed
(sperm number, motility and normal morphology per-
centages - Figs. 5A and 5B) were significantly increased
when compared to those corresponding to the 90D sub-
group. However, although sperm concentration and nor-
mal morphology observed in amifostine/doxorubicin-
treated rats showed an improvement in comparison to
those obtained from the D group, it was still reduced
when compared to the rats of the SC and A groups.
Reproductive competence
The number of fetuses obtained from the females mated
with rats from the 90D and 90AD subgroups was
decreased when compared to the number of fetuses
observed in the females mated with rats from the 90SC
and 90A subgroups (Fig. 5C). Interestingly, the 90AD
subgroup had a lower fertility index when compared to
the 90D subgroup as well.
Figure 3 Photomicrographs of testicular sections of Sham Control, Amifostine, Doxorubicin and Amifostine/Doxorubicin treated rats
at different ages. PAS+H method. Portions of seminiferous tubule sections of 90-day-old rats. A and B: Sham Control (A) and Amifostine (B)
groups showing normal organization of the seminiferous epithelium. C and D: Doxorubicin-treated group; in C, tubular sections with partial
depletion of the seminiferous epithelium are noted; some areas of discontinuity in the germ cell layers can be observed (arrows); in D, a tubular
section with accentuated cellular depletion and showing Sertolization is shown. E and F: Amifostine/Doxorubicin-treated group; in both figures,
note the concentric and normally organized germ cell layers of the seminiferous epithelium; pachytene spermatocytes (thick arrows); Sertoli cell
nucleus (S); round spermatids (arrowheads); elongated spermatids (long arrows); tubular lumen (TL).
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Discussion
The results of this study showed that amifostine pro-
motes an improvement of some testicular and seminal
parameters, suggesting that amifostine reduced the
doxorubicin toxicity on the male gonad. However, the
analysis of the data, which were obtained after the
elapsed time of sixty days (from treatment to the
euthanasia of 90D and 90AD rats), showed that the
amifostine pre-treatment did not guarantee fertility
improvement of the sequentially doxorubicin-treated
animals, although some reduction of testis damage and
an improvement of the sperm concentration, motility
and morphology have been observed. The protective
capacity of amifostine over some other tissues has
already been proven to be effective against the deleter-
ious action of gamma irradiation, taxanes, antracyclines
and platinum derivatives [5,16,17,21,23,37].
Both doxorubicin and amifostine doses chosen to be
used in this study were based on previous findings.
Doxorubicin is usually administered to adult rats in
doses up to 21 mg/kg [38,39]. In rodents, the single
dose of 5 mg/kg of body weight provokes disruption
on spermatogenic cells maturation, epididymis sperm
concentration reduction, alterations of spermatogonia
DNA and sperm morphology [40]. The aim of this
study was to verify if a single dose of amifostine could
reduce the long-term side effects on the seminiferous
epithelium of sexually immature and adult rats, pro-
voked by a unique cytotoxic dose of doxorubicin admi-
nistered in the prepuberty. On the same way, the
single dose of 400 mg/Kg of amifostine was selected
due to its testicular minimal toxicity which could be
neglected, as described by Meistrich and co-workers in
murine assays [41]; on the other hand, single higher
doses or multiple lower doses have been referred to be
toxic to the stem spermatogonia, diminishing their sur-
vival [15,41].
Few studies on the association of amifostine and dox-
orubicin in cancer therapy have been recently carried
out; some of them produced contradictory results
regarding the protection of the bone marrow and of car-
diac and testicular tissues [25-28]. Therefore, amifostine
potential protection against doxorubicin testicular toxi-
city seems to be a very delicate issue. Thus, we decided
to carry out a detailed morphometric and stereological
analyses of rat testes which constitute important
unbiased tools to study biological tissue damages.
The alteration of the measurements of testicular
volume and weight, for example, suggests injury of the
gonad. In addition, parameters such as tubular diameter,
seminiferous epithelium height and volume densities of
tubular lumen and seminiferous epithelium can also
give information about the testicular damage degree as a
consequence of germ cell death. França and Russell [42]
have mentioned that when a massive germ cell loss
occurs, it is followed by a sharp decline in testicular
morphometric parameters. In general, germ cell death
caused by anticancer drugs, including doxorubicin
[43,44], culminates with a reduction of morphometric
parameters [24,33]. However, our data suggest that
germ cell loss is not necessarily associated with the
reduction of these parameters since the occurrence of
other phenomenon can interfere in the final establish-
ment of the testis weight [24]. In fact, alterations of tes-
ticular weight were not observed in doxorubicin and
amifostine-treated rats; since germ cell loss was noticed,
Table 1 Stereological measurements, expressed in percentages, obtained from the testicular components of rats of
the SC, A, D and AD groups in three different phases of sexual maturation (Mean ± std. dev.)
Group Volume Density - Vv (%)
VvTL VvEp VvIT VvLS
45SC 10.12 ± 1.12 66.64 ± 2.31 8.76 ± 0.89 14.48 ± 2.87
45A 9.02 ± 0.80c 62.38 ± 4.40 7.76 ± 0.78a, c 20.84 ± 4.52 a
45D 11.46 ± 1.19 a, b, d 65.56 ± 2.09 6.64 ± 0.64 a, b 16.34 ± 2.00
45AD 9.40 ± 0.54 c 64.68 ± 1.29 6.64 ± 0.41a 19.26 ± 1.86
60SC 5.38 ± 0.65 64.32 ± 1.37 9.70 ± 0.44 20.74 ± 1.13
60A 7.42 ± 0.47 a, c, d 69.30 ± 1.92 a, c 9.18 ± 0.28 c 14.10 ± 1.98a, c
60D 10.56 ± 1.32 a, b, d 58.22 ± 2.24a, b, d 8.42 ± 0.49a, b 22.80 ± 2.61b, d
60AD 9.28 ± 0.37 a, b, c 70.00 ± 1.52 a, c 8.42 ± 0.75 a 12.50 ± 1.87a, c
90SC 10.82 ± 0.58 65.48 ± 2.33 9.30 ± 0.36 15.16 ± 1.43
90A 11.78 ± 1.07 c, d 65.00 ± 3.21c, d 8.78 ± 0.76 c, d 14.42 ± 3.33d
90D 16.40 ± 1.92a, b, d 57.60 ± 2.35a, b, d 6.80 ± 0.60a, b, d 19.20 ± 2.32d
90AD 8.54 ± 0.52a, b, c 61.70 ± 1.59b, c 7.94 ± 0.51 a, b, c 22.00 ± 2.05 a, b, c
Volume Densities (Vv): Tubular Lumen (VvTL); Seminiferous Epithelium (VvEp);
Interstitial Tissue (VvIT); Lymphatic Space (VvLS)
P < 0.05 (significant): a = significant when compared to SC; b = significant when compared to A; c = significant when compared to D; d = significant when
compared to AD
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the unaltered weight might be a consequence of a lym-
phatic and/or interstitial edema that counterbalance
germ cell death and the organ weight. Interstitial edema
is a testicular injury and a direct consequence of
endothelial layer disruption, which liberates fluids from
blood flow into interstitial tissue. Thus, testicular inter-
stitial fluid volume can be increased by a variety of fac-
tors including testosterone level alterations [45] and
toxic exposure [24,46,47]. Indeed, doxorubicin causes
endothelial dysfunction and edema, as secondary effects
of oxidative stress in the vascular wall. The vascular
endothelium plays a fundamental role in maintenance of
organ function by forming a barrier regulating water
and solute distribution between blood and tissues; how-
ever, this fluid control can be deregulated by oxidative
stress [48], resulting in movement of water and proteins
from the vascular system into tissues and compromising
organ function. In fact, in 90-day-old rats of the AD
group, for example, the lymphatic capillary volume den-
sity was conspicuously increased when compared to the
other corresponding groups in the same age. Future
studies must be carried out to clarify the effects of ami-
fostine on testis interstitial tissue, and the impact of the
interaction of the amifostine and doxorubicin on the
hormonal regulation of the male reproductive system,
the endothelial dysfunction and testicular edema occur-
rence, as well as their roles on the morphophysiology of
the interstitial tissue.
In spite of the adverse effects observed on the lympha-
tic space volume density, it was noted a distinctive
reduction of the seminiferous epithelium damage in the
60-day-old rats treated with amifostine/doxorubicin, in
comparison to those solely doxorubicin-treated. Indeed,
amifostine seems to reduce the damage and the germ
cell loss caused by the acute doxorubicin treatment and
this can be confirmed when the present data related to
the epithelium height and volume density from the 60-
and 90-day-old doxorubicin-treated rats previously trea-
ted or not with amifostine were compared. The analysis
of the spermatogonia frequencies also corroborates this
idea. The depletion of seminiferous epithelium and the
consequent decrease of morphometric and stereological
Figure 4 Seminiferous tubule diameter morphometry in rats of the SC (Sham Control), A (Amifostine), D (Doxorubicin) and AD
(Amifostine/Doxorubicin) groups at the 3 ages studied. Seminiferous tubule diameter (4A) and the growth rates (4B) observed in the
different groups. 4C: Box plots illustrating the median of the seminiferous epithelium height. The median for each dataset is indicated by the
line in the boxes which in themselves contain 50% of the data. The upper and lower hinges of the boxes indicate the 25-75 percentiles. Values
within 1.5 times the interquartil range are indicated by the lines. Mean values +/- standard deviation; P < 0.05 (a, b, c, d, e, f). Labels - 4A: a = A
and AD < SC and D; b = D < SC, A and AD; c = A and AD > D; d = A > AD; e = D > AD;f = AD < SC, A and D. 4C: a = A and AD > D; b = D
< SC, A and AD; c = A > D and AD; d = D < SC, A and AD; e = AD < SC and A.
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measurements caused by cytotoxic agents were shown
by Meistrich [8] and were confirmed in our report. As
previously referred, a significant reduction of the fre-
quency of tubules containing at least one type of differ-
entiated spermatogonia (types A, Intermediate and B)
occurred in the doxorubicin groups, in comparison to
the amifostine-pretreated groups. Although spermatogo-
nia are not the only cell type of the seminiferous epithe-
lium under continuous division, their localization in the
basal portion of the epithelium make them more vulner-
able to the action of cytotoxic drugs [7,14,33].
Considering that, in rats, the complete seminiferous
epithelium cycle lasts 12 days [49,50], we can suppose
that, according to the elapsed time between treatment
and the euthanasia of the animals applied in our study
(15, 30 or 60 days), the cells generated from the target
spermatogonia were: pachytene spermatocytes at 15
days; round spermatids at 30 days and mature sperm
that reach the epididymis cauda at 60 days [51]. Even
though the total number of each cell type was not quan-
tified in the current study, we can assume based on the
results that there was higher cell loss from the semini-
ferous tubules in the solely doxorubicin-treated rats in
comparison to those which were previously amifostine-
treated. On the other hand, it is plausible to consider
that the progression of cellular maturation could be
deregulated by amifostine treatment based on the altera-
tions of the frequencies of tubular sections containing
intermediate spermatogonia and spermatids, which were
observed in the 45-day-old rats from amifostine-treated
subgroups (45A and 45AD). We believe that such altera-
tion might have occurred due to one of the amifostine
protective mechanisms of DNA interaction, i.e., produ-
cing its stabilization and inhibiting nuclear proteins,
such as topoisomerase II [52] and DNA-polimerase [53],
which were involved in cell division. Thus, while inter-
calated with the DNA, amifostine prevents doxorubicin
linkage with cell DNA [20]. The decreased frequency of
tubular sections with spermatids observed in 45AD sub-
group, even when compared to 45A subgroup, might
have occurred as a consequence of interference on the
cell cycle caused by amifostine-doxorubicin association
[37]. Nevertheless, this effect was reversible since it was
only detected in 45-day-old rats.
It is important to emphasize that two studies carried
out by a same group have shown amifostine toxicity to
6-day-old rat germ cells when associated with doxorubi-
cin [26,28]. In their most recent study they have sug-
gested that the treatment with amifostine (200 mg/kg)
prior to doxorubicin (3 mg/kg b.w.) did not provide any
protection against apoptosis induced in rat stem sper-
matogonia of 6-day-old rats, whereas 16- and 24-day-
old animals did not show increase of cell death caused
by doxorubicin [28]. Considering the low dose used in
the aforementioned study, it is probable that the semini-
ferous epithelium of 16-day-old rats is more resistant to
the doxorubicin than that of the 6-day-old rats, since
the hematotesticular barrier begins to be established at
the age of 15 days, according to Schulze [54]. As pre-
viously demonstrated by our group, 30-day-old rats did
not show considerable toxicity after treatment with a
400 mg/kg single dose of amifostine [24]. On the other
hand, the chosen dose of doxorubicin used in the pre-
sent experiment was unable to cause mortality or reduc-
tion of body weight in rats at all studied ages, although
morphological damages of seminiferous epithelium have
occurred as a consequence of its cytotoxicity.
Doxorubicin is known to produce apoptosis [28,43] on
dividing cells, as etoposide [33]. Our histological find-
ings suggest that doxorubicin cytotoxicity was responsi-
ble for producing the frequently observed apoptotic
Table 2 Frequencies of the different types of germinal
lineage cells per 100 tubular sections examined in rat
testes of the SC, A, D and AD groups, in three different
phases of sexual maturation (Mean ± std. dev.)
Group Cell Type (%)
GA GIn GB
45SC 72.40 ± 3.05 b, c, d 42.00 ± 4.95 b, c, d 54.00 ± 4.95b, c, d
45A 75.80 ± 1.92a, c, d 51.20 ± 4.02 a, c 29.60 ± 4.15a
45D 65.80 ± 2.49a, b 33.80 ± 3.56a, b, d 24.80 ± 3.96a
45AD 66.80 ± 1.48a, b 56.00 ± 4.74a, c 27.20 ± 6.27a
60SC 85.20 ± 3.56c 60.00 ± 5.52b, c 67.20 ± 5.76c, d
60A 88.00 ± 2.23c, d 74.80 ± 3.34a, c, d 66.00 ± 5.00c, d
60D 77.00 ± 2.55a, b, d 49.00 ± 3.97a, b, d 39.40 ± 7.02a, b, d
60AD 83.20 ± 3.03b, c 59.60 ± 5.94b, c 48.60 ± 4.33a, b, c
90SC 97.20 ± 1.30b, c, d 48.40 ± 4.98b, d 53.00 ± 3.93b, c, d
90A 100.00 ± 0.00a, c, d 62.60 ± 3.64a, c, d 43.40 ± 3.05a, b, d
90D 89.80 ± 1.92a, b, d 44.80 ± 3.03b 27.00 ± 0.94a, b, d
90AD 93.20 ± 2.77a, b, c 41.80 ± 2.58a, b 35.68 ± 1.28a, b, c
PS RS ES
45SC 99.80 ± 1.05 72.60 ± 3.64 99.00 ± 1.00b, d
45A 100.00 ± 1.00 73.40 ± 2.70 84.20 ± 5.26a, c, d
45D 99.80 ± 1.20 72.80 ± 7.91 98.00 ± 2.00b, d
45AD 99.80 ± 1.05 78.40 ± 1.81 74.00 ± 11.95a, b, c
60SC 100.00 ± 0.03 83.60 ± 3.57c, d 98.40 ± 2.07
60A 100.00 ± 0.02 82.40 ± 1.94c, d 99.00 ± 1.22
60D 100.00 ± 0.03 73.60 ± 3.43a, b 97.00 ± 4.58
60AD 99.80 ± 0.03 77.20 ± 4.76a, b 99.20 ± 1.09
90SC 100.00 ± 0.01 85.60 ± 2.19c 99.90 ± 0.44
90A 100.00 ± 0.00 85.80 ± 1.92c 100.00 ± 0.00
90D 99.60 ± 0.50 71.60 ± 2.40a, b, d 98.60 ± 1.34
90AD 99.40 ± 0.80 82.20 ± 4.14c 99.40 ± 0.89
GA: Type A spermatogonia; GIn: Intermediate spermatogonia; GB: Type B
spermatogonia; PS: Primary spermatocyte; RS: Round spermatids; ES:
Elongated spermatids
P < 0.05 (significant): a = significant when compared to SC; b = significant
when compared to A; c = significant when compared to D; d = significant
when compared to AD
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round spermatids and multinucleated apoptotic cells.
The intercalation of doxorubicin in the germ cell DNA
during division is considered to be the principal cause
of cellular death induction in the seminiferous epithe-
lium [9,43]. Even escaping from death, the cells affected
by doxorubicin can still have its genome damaged, pro-
voking further impairments on cell progression [55].
Confirming our histological findings, sperm analysis
from the epididymal fluid also suggests that amifostine
could confer partial protection for cell survival. The sig-
nificantly higher sperm concentration obtained in prior-
amifostine-treated rats leads us to believe that there
were a higher number of resistant spermatogonia in
these animals. However, reproductive competence
results alerted us about the level of the protection con-
ferred by amifostine against the potential damage pro-
duced on sperm membrane and DNA integrity after
doxorubicin exposure. Under the experimental condi-
tions used here, amifostine conferred some germ cell
protection against doxorubicin probably by preventing
apoptosis of healthy and genetically damaged spermato-
gonia. If spermatogonia with harmed DNA survived, it
is possible that they produced sperm with damaged
DNA, although good sperm motility and morphology
Figure 5 Graphics illustrating the sperm parameters and the fertility index of 90-day-old rats, obtained from the SC (Sham Control), A
(Amifostine), D (Doxorubicin) and AD (Amifostine/Doxorubicin) groups. 5A: Box plots showing the median for sperm concentration in each
group indicated by the line in the boxes which in themselves contain 50% of the data. The upper and lower hinges of the boxes indicate the
25-75 percentiles. Values within 1.5 times the interquartil range are indicated by the lines. 5B: Percentage of sperm that displayed any type of
movement and normal morphology; 5C: Fertility index. Mean values +/- standard deviation; P < 0.05 (a and b). Labels - 5A: a = D < SC, A and
AD; b = AD < SC and A. 5B: a = D < SC, A and AD; b = AD < SC and A. 5C: a = D < SC and A; b = AD < SC, A and D.
Vendramini et al. Reproductive Biology and Endocrinology 2010, 8:3
http://www.rbej.com/content/8/1/3
Page 11 of 13
have been observed. Thus, the sperm with damaged
DNA would be able to compete with normal sperm and
produce abnormal embryos, what leads to the conclu-
sion that such improvement in spermatogonia survival
is disadvantageous for reproduction and embryo devel-
opment. These subjects are under investigation.
Conclusions
Nowadays, the impairment of infertility remains a strug-
gle for surviving patients who have undergone che-
motherapy treatment, especially during childhood. As
demonstrated in the current study, the testicular cyto-
toxicity caused by doxorubicin provokes serious germ
cell depletion in the seminiferous epithelium of prepu-
bertal rats. Our results have shown a reduction of semini-
ferous epithelium damage caused by doxorubicin and an
improvement of the epididymal fluid sperm parameters
in previously amifostine-treated rats; thus, they have
pointed out for a partial protection of germ epithelium,
although the aspects related to the combined administra-
tion of amifostine and doxorubicin and its impact on the
germ cell genome components must be clarified. Sperma-
togonia survival promoted by amifostine was disadvanta-
geous when doxorubicin was taken together, leading to
reduced reproductive outcome. In this scope, sperm
DNA integrity and its future contribution to the subse-
quent generation health might be a concern. Thence-
forth, more detailed studies are necessary to investigate
how they interact when concomitantly administered. In
order to explore the potential cytoprotective benefits of
amifostine, the protocols of administration and the age of
treatment must be carefully considered.
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